Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ANTX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-0.79
vs -2.98
Q2.23
N/A
-0.81
vs -0.53
Q3.23
N/A
-0.65
vs -0.59
Q4.23
N/A
-0.57
vs -0.61
Q1.24
N/A
-0.56
vs -0.79
Q2.24
N/A
-0.48
vs -0.81
Q3.24
N/A
-0.43
vs -0.65
Q4.24
N/A
-0.25
vs -0.57
Q1.25
N/A
-0.26
vs -0.56
Q2.25
N/A
-0.26
vs -0.48
Sales Growth
YoY
Current
Estimates
Q3.22
NA
NA vs NA
Q4.22
NA
NA vs NA
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
80K vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
-100%
NA vs 80K
Return on Equity
QoQ
Q1.23
-18%
-0.18
vs -0.13
Q2.23
-18%
-0.18
vs -0.18
Q3.23
-12%
-0.12
vs -0.18
Q4.23
-14%
-0.14
vs -0.12
Q1.24
-15%
-0.15
vs -0.14
Q2.24
-15%
-0.15
vs -0.15
Q3.24
-15%
-0.15
vs -0.15
Q4.24
-9%
-0.09
vs -0.15
Institutionnal Ownership
QoQ
Q1.23
37
37
vs 35
6%
Q2.23
31
31
vs 37
-16%
Q3.23
37
37
vs 31
19%
Q4.23
51
51
vs 37
38%
Q1.24
54
54
vs 51
6%
Q2.24
45
45
vs 54
-17%
Q3.24
31
31
vs 45
-31%
Q4.24
37
37
vs 31
19%
businesswire.com
7 hours ago
businesswire.com
7 hours ago
businesswire.com
16 hours ago
businesswire.com
16 hours ago
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.04Â ( -3.10%)
Relative Strenght
22
Volume Buzz
-34%
Earning Acce
Yes
Dist 52w H.
59%Forecast
NaN%2025-Revenue
-325%2025-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Evercore ISI
downgradePrevious: Not converted
2024-08-09
Now: Underperform
Leerink Partners
upgradePrevious: Market Perform
2024-07-03
Now: Outperform
JMP Securities
upgradePrevious: Not converted
2024-04-02
Now: Outperform
Leerink Partners
downgradePrevious: Not converted
2024-02-13
Now: Market Perform
Relative Strength
ANTX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
